November 23rd, 2023

RegMed Forum 2023 -ATMPs – Thinking Big, Inclusive and Beyond **Rare Disease!**

BCRT - Cranach Haus -Föhrerstr. 15 | 13353 Berlin













Prog	ramme Moderation: Timo Nazari-	ration: Timo Nazari-Shafti	
Foyer			
08:30	Registration	45'	
_	Auditorium	451	
09:00	Welcome	15'	
	Timo Nazari-Shafti (BIH Center für Regenerative Therapien, Deutsches Herzzentrum Berlin)		
	Jasmin Podufall (Berlin Partner) Christopher Baum – video welcome (Berlin Institute of Health)		
Scient	ific Input and Discussion		
	•	20'	
09:15	Keynote	20	
	Atta Behfar (Mayo Clinic – online)		
	Lead question : How can patients shape novel therapy developments? (vision		
	or use-cases)		
09:30	Patient representative (Peter Böhm)	5'	
09:40	Patient (Field: Cardio)	5'	
09:45	Patient (Field: Cardio)	5'	
09:50	Panel Discussion	45'	
09:50	Patiet Discussion	45	
	 Ruth Biller (European Patient Advocacy Group in the ERN GUARD-Heart, Founding member of ARVC-Selbsthilfe e.V.) 		
	 André Berger (Innovation Office Paul-Ehrlich-Institute) 		
	 Maximilian Emmert (University of Zurich, Charité, Deutsches Herzzentrum Berlin) 		
	 Olaf Weber (Entrepreneur and advisor, former head of R&D Radiology at Bayer) 		
	Lead question: Requirements for inclusive ATMP development for common		
	diseases		
Foyer			
10:35	Coffee Break	25'	
Foyer or	Auditorium		

30'

RegMed Forum 2023 -ATMPs – Thinking Big, Inclusive and Beyond Rare Disease!

Foyer **Wrap Up**

15:30

16:00

End of Programme

BCRT – Cranach Haus – Föhrerstr. 15 | 13353 Berlin

11:00 Intro	duction World Coffee (Timo Nazari-Shafti)	5'
11.00 IIItro	duction world conee (111110 Nazari-Snaja)	Э
Seminar room B	(0.0028)	
•	Lead question: How can PROMs be brought into greater use? How can we better represent different patient views. How can we integrate the patient perspective more strongly in the conduct of clinical trials?	20' per round
Cafeteria (0.0031		00'
•	World Coffee "Regulatory Affairs" (Christoph Conrad) <u>Lead question</u> : Which regulatory aspects could strengthen and further the innovative potential in Germany? How to de-risk ATMP clinical trials from a regulatory perspective? How to better interact with regulatory instances?	20' per round
Seminar room A	•	001
•	· · · · · · · · · · · · · · · · · · ·	20' per round
Auditorium (0.00		
•	World Coffee "Clinical" (Timo Nazari-Shafti) <u>Lead question:</u> How would an optimal hub for ATMP development look like? Which are barriers for ATMP developments? What can we learn from other hub-like structures?	20' per round
13:00 Luncl	n + Industrial Exhibition	90'
•	Cellink Therycell	
Results Brea	kouts:	
14:30 Worl 14:45 Worl	d Coffee "Patients" d Coffee "Regulatory Affairs" d Coffee "Industry" d Coffee "Clinical"	15' 15' 15' 15'

Wrap Up and Networking Coffee (Timo Nazari-Shafti, all)